- Home
- PDD vs BMY Comparison
PDD vs BMY Comparison
Compare PDD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDD
- BMY
- Stock Information
- Founded
- PDD 2015
- BMY 1887
- Country
- PDD Ireland
- BMY United States
- Employees
- PDD N/A
- BMY N/A
- Industry
- PDD Business Services
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- PDD Consumer Discretionary
- BMY Health Care
- Exchange
- PDD Nasdaq
- BMY Nasdaq
- Market Cap
- PDD 139.0B
- BMY 120.4B
- IPO Year
- PDD 2018
- BMY N/A
- Fundamental
- Price
- PDD $98.94
- BMY $57.28
- Analyst Decision
- PDD Strong Buy
- BMY Hold
- Analyst Count
- PDD 10
- BMY 15
- Target Price
- PDD $173.40
- BMY $55.93
- AVG Volume (30 Days)
- PDD 11.3M
- BMY 11.6M
- Earning Date
- PDD 11-21-2024
- BMY 02-06-2025
- Dividend Yield
- PDD N/A
- BMY 4.33%
- EPS Growth
- PDD 133.06
- BMY N/A
- EPS
- PDD 10.49
- BMY N/A
- Revenue
- PDD $53,048,260,958.00
- BMY $47,435,000,000.00
- Revenue This Year
- PDD $62.39
- BMY $7.22
- Revenue Next Year
- PDD $24.98
- BMY $0.16
- P/E Ratio
- PDD $9.48
- BMY N/A
- Revenue Growth
- PDD 87.39
- BMY 5.56
- 52 Week Low
- PDD $88.01
- BMY $39.35
- 52 Week High
- PDD $164.69
- BMY $61.08
- Technical
- Relative Strength Index (RSI)
- PDD 39.62
- BMY 50.79
- Support Level
- PDD $99.60
- BMY $55.04
- Resistance Level
- PDD $103.66
- BMY $58.55
- Average True Range (ATR)
- PDD 2.84
- BMY 1.28
- MACD
- PDD 0.56
- BMY -0.31
- Stochastic Oscillator
- PDD 13.37
- BMY 44.36
About PDD PDD Holdings Inc.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.